Aktienanalyse wird geladen …
JNJ · NYSE · Pharmaceuticals · USA
271,22 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 94,19 Mrd. | 26,8 Mrd. | 11,03 $ | 2,43 Mrd. | 5 Mio · 0,2 % | 5 Mio · 0,2 % | 67,9 % | 28,5 % | 8,11 $ | 0,56 $ | 5,14 $ |
| 2024 | 88,82 Mrd. | 14,07 Mrd. | 5,79 $ | 2,43 Mrd. | 4,3 Mio · 0,2 % | 135 Mio · 5,6 % | 69,1 % | 15,8 % | 8,17 $ | 0,48 $ | 4,91 $ |
| 2023 | 85,16 Mrd. | 35,15 Mrd. | 13,72 $ | 2,56 Mrd. | 4,3 Mio · 0,2 % | 108 Mio · 4,2 % | 68,8 % | 41,3 % | 7,13 $ | 0,45 $ | 4,70 $ |
| 2022 | 79,99 Mrd. | 17,94 Mrd. | 6,73 $ | 2,66 Mrd. | 4,2 Mio · 0,2 % | 14,3 Mio · 0,5 % | 69,3 % | 22,4 % | 6,45 $ | 0,43 $ | 4,45 $ |
| 2021 | 78,74 Mrd. | 20,88 Mrd. | 7,81 $ | 2,67 Mrd. | 4,2 Mio · 0,2 % | 0,9 Mio · 0 % | 70,3 % | 26,5 % | 7,39 $ | 0,42 $ | 4,19 $ |
| 2020 | 82,58 Mrd. | 14,71 Mrd. | 5,51 $ | 2,67 Mrd. | 3,7 Mio · 0,1 % | 17,3 Mio · 0,6 % | 65,6 % | 17,8 % | 7,56 $ | 0,38 $ | 3,98 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 25,31 Mrd. | 5,53 Mrd. | 2,27 $ | 2,44 Mrd. | 68,2 % | 21,9 % | 2,99 $ |
| Q1 2026 | 24,06 Mrd. | 5,24 Mrd. | 2,14 $ | 2,45 Mrd. | 66,3 % | 21,8 % | 0,60 $ |
| Q4 2025 | 24,56 Mrd. | 5,12 Mrd. | 2,11 $ | — | 67,6 % | 20,8 % | 2,25 $ |
| Q3 2025 | 23,99 Mrd. | 5,15 Mrd. | 2,12 $ | 2,43 Mrd. | 69,6 % | 21,5 % | 3,30 $ |
| Q2 2025 | 23,74 Mrd. | 5,54 Mrd. | 2,29 $ | 2,42 Mrd. | 67,9 % | 23,3 % | 1,17 $ |
| Q1 2025 | 21,89 Mrd. | 11 Mrd. | 4,54 $ | 2,42 Mrd. | 66,4 % | 50,2 % | 1,39 $ |
| Q4 2024 | 22,52 Mrd. | 3,43 Mrd. | 1,41 $ | — | 68,4 % | 15,2 % | 2,21 $ |
| Q3 2024 | 22,47 Mrd. | 2,69 Mrd. | 1,11 $ | 2,43 Mrd. | 69 % | 12 % | 2,87 $ |
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement
Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care. The company serves hospitals, clinicians, patients, and healthcare systems in markets around the world, making it a central participant in both drug development and medical device supply chains. Johnson & Johnson is known for operating at the intersection of large-scale research, clinical innovation, and essential healthcare delivery, with products that support prevention, treatment, diagnosis, and recovery across a wide range of medical settings.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest JNJ und jede andere Aktie unbegrenzt.